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ABSTRACT
Introduction: Systemic sclerosis (SSc) is a rare and complex connective tissue disease characterized by
fibrosis of the skin and internal organs. Interstitial lung disease (ILD) is a common complication of SSc
and the leading cause of SSc-related death. No drugs are licensed for the treatment of SSc-ILD.
Areas covered: This review provides an overview of the current treatment of SSc-ILD and a perspective
on investigational therapies, focusing on those studied in randomized controlled trials.
Expert opinion: There is substantial room for improvement in the treatment of SSc-ILD. Current
treatment focuses on immunosuppressant therapies, particularly cyclophosphamide and mycopheno-
late. Hematopoietic stem cell transplantation has been shown to improve long-term outcomes, but the
risk of treatment-related mortality restricts its use to select patients at specialized centers. Modifying the
course of disease to improve outcomes remains the goal for new therapies. Several drugs are under
investigation as potential therapies for SSc-ILD, providing hope that the limited treatment armamentar-
ium for SSc-ILD will be expanded and improved in the near future. Expert consensus is needed on how
to screen for and monitor SSc-ILD and on when to initiate and escalate therapy.
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1. Introduction
Systemic sclerosis (SSc) is a rare and complex connective
tissue disease (CTD) characterized by fibrosis of the skin and
internal organs [1]. While the exact cause of SSc is unknown, it
is believed to involve an abnormal response to microvascular
injury in individuals with genetic susceptibility and/or epige-
netic modifications, which leads to immune dysregulation,
inflammation, microvasculopathy and fibrosis [2,3]. SSc may
be classified according to the degree of skin involvement into
limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc
(dcSSc) [4]. The clinical course of SSc is highly variable, neces-
sitating regular monitoring for the development and progres-
sion of specific organ manifestations [1,5].
Interstitial lung disease (ILD) occurs in the majority of patients
with SSc and is a leading cause of SSc-related death [6]. Risk
factors for the development of SSc-ILD include dcSSc [7], African-
American ethnicity [8], shorter disease duration [9], older age at
disease onset [7], and the presence of anti-topoisomerase
I antibody and/or absence of anticentromere antibody [7].
Cough and dyspnea are common in patients with SSc-ILD [10]
and may compromise patients’ quality of life [11,12]. Pulmonary
hypertension, which may or may not be associated with the
underlying SSc or ILD, is common in patients with SSc-ILD and
is associated with high mortality [13,14].
ILD typically occurs early in the course of SSc, particularly in
patients with dcSSc (Figure 1) [7,9]. The clinical course of SSc-ILD
is variable: some patients show stability in FVC while others show
a progressive decline in lung function [15]. Pulmonary function
tests (PFTs) alone may not be sensitive enough to detect SSc-ILD
[16] and visual analysis of high-resolution computed tomogra-
phy (HRCT) images is the gold standard tool for screening. The
histological pattern most commonly observed in SSc-ILD is non-
specific interstitial pneumonia (NSIP), which is observed in
approximately two-thirds of patients [17]. Usual interstitial pneu-
monia (UIP) is present in a minority of individuals with SSc-ILD
[17–19] andmay be associated with poorer outcomes [20]. There
is growing interest in the use of quantitative analysis of HRCT to
assess disease extent and monitor progression in patients with
SSc-ILD [21,22] but this is not yet feasible for use in everyday
clinical practice.
The extent of fibrosis on HRCT predicts the progression of
ILD [23]. In a seminal study, the presence of extensive disease
(disease extent on HRCT >30%, or 10-30% plus FVC <70%
predicted) was a strong predictor of early mortality [24]. In
a study following 172 patients with SSc-ILD over 3.5 years,
a disease extent on HRCT >20% was associated with a three-
fold increased risk of progression of SSc-ILD (defined as the
use of home oxygen or lung transplantation) or death com-
pared to patients with a disease extent <20% on HRCT [25]. In
an analysis of 519 patients with SSc who had HRCT scans at
baseline, the standardized mortality rate (compared to
a control group matched by gender, age, and year of birth)
increased with the extent of lung fibrosis on HRCT, from 2.2 in
patients with no fibrosis to 8.0 in patients with an extent of
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lung fibrosis >25% [26]. Decline in lung function is also
a predictor of mortality in patients with SSc-ILD [27,28].
A study of 49 patients with extensive lung fibrosis showed
that a decline in FVC of ≥10%, or a decline in FVC of 5–9%
with a decline in DLco of >15%, was the most important
predictor of mortality over a 15-year follow-up [27]. In an
analysis of data from patients treated in Scleroderma Lung
Study (SLS) I (n = 158) and SLS II (n = 142), FVC % predicted
and DLco % predicted measured as time-varying covariates
over 2 years were independently associated with long-term
mortality [28].
In this article, we provide an overview of the current treat-
ment of SSc-ILD and a perspective on investigational treat-
ments, focusing on the therapies studied in randomized
controlled trials.
2. Current treatment of SSc-ILD
There is no established algorithm for the management of SSc-ILD,
but patients with advanced ILD on HRCT, or ILD plus a decline in
lung function or symptoms, generally undergo treatment with
immunosuppression [29–33]. The treatment recommendations
for SSc issued by the European League Against Rheumatism
(EULAR) use a stringent selection of randomized controlled trials
as supportive evidence. The latest recommendations, issued in
2016, support the use of tailored therapy with cyclophosphamide
(CYC), particularly for patientswith progressive ILD, while acknowl-
edging the need to consider the risk-to-benefit ratio for individual
patients [34,35]. A recommendation for mycophenolate mofetil
(MMF) was not included in the latest EULAR treatment guidelines,
because the results of the SLS II [36] were not published when the
recommendations were developed.
The selection of therapy for SSc-ILD is highly variable. An
online survey of 445 pulmonologists and rheumatologists from
7 countries conducted in 2017 found that while almost half of
respondents used corticosteroids as first-line therapy, there was
great heterogeneity in second- and third-line therapies, with
CYC, azathioprine, MMF, methotrexate, and rituximab all being
chosen as second-line therapies by at least 9% of respondents
[37]. In algorithms for the treatment of SSc-ILD developed in
2016–2017, the consensus of experts was that MMF, intravenous
CYC and rituximab should be used as first-, second- and third-line
induction therapy, and MMF, azathioprine and CYC (intravenous
or oral) should be used as first-, second- and third-line mainte-
nance therapy, respectively [38]. Recent Delphi consensus stu-
dies conducted among rheumatologists and pulmonologists
with expertise in managing patients with SSc-ILD also supported
the use of MMF as first-line therapy [39,40]. In clinical practice,
selection of therapy is based on a variety of factors, including
access to therapies, a belief in the superiority of a specific agent,
as well as a desire to provide patients with a treatment of some
kind even in the absence of approved therapies.
Article highlights
● SSc is a rare and complex connective tissue disease with an unpre-
dictable clinical course. ILD is a common manifestation of SSc and is
the leading cause of death related to SSc.
● There is no established treatment algorithm for SSc-ILD, but patients
with advanced or progressive disease generally receive immunosup-
pression. CYC and MMF are the most commonly used therapies,
based on the results of randomized controlled trials.
● Hematopoietic stem cell transplantation (HSCT) has been shown to
improve outcomes in patients with rapidly progressive SSc at risk of
organ failure, but its use is restricted to highly selected patients
treated at specialized centers due to the risk of treatment-related
mortality.
● There is a high unmet need for disease-modifying treatments for SSc-
ILD with an acceptable side-effect profile. Several therapies are under
investigation as treatments for SSc-ILD. Nintedanib has recently been
shown to slow the progression of ILD in patients with SSc-ILD, with
a side-effect profile that was manageable for most patients.
● The discovery of biomarkers would facilitate the identification of
patients most likely to benefit from specific therapies and so enable
a precision medicine approach to treatment.
Figure 1. ILD occurs early in the course of SSc.
Adapted with permission from: Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study. Jaeger et al. [9].
1010 O. DISTLER ET AL.
2.1. Cyclophosphamide
The EULAR recommendation for use of CYC in the treatment
of SSc-ILD was based on the results of two randomized pla-
cebo-controlled trials: the Fibrosing Alveolitis in Scleroderma
Trial (FAST) [41] and SLS I [42]. In FAST, in which 45 subjects
received oral prednisolone on alternate days plus monthly
intravenous infusions of CYC for 6 months followed by oral
azathioprine for 6 months, or placebo for 12 months, there
was an improvement of 2.4% in FVC % predicted with active
treatment versus a decline of 3.0% with placebo (p = 0.08)
[41]. In SLS I, there was a significant benefit of CYC versus
placebo in the primary endpoint of change from baseline in
FVC % predicted at month 12 (−1.0 versus −2.6% predicted),
as well as in a number of secondary endpoints, including total
lung capacity (TLC) % predicted, radiographic extent of fibro-
sis, dyspnea and health-related quality of life [42]. Differences
in FVC % predicted with CYC versus placebo at month 12 were
greater in subjects with FVC <70% predicted at baseline [43].
Further, a retrospective regression analysis showed that
patients with a greater extent of disease on HRCT and/or
greater extent of skin disease (higher score on the modified
Rodnan skin score) were more likely to respond to CYC [44].
Adverse events that were more common in the CYC group
included leukopenia (26.0% versus 0%), hematuria (12.3% ver-
sus 4.2%), neutropenia (9.6% versus 0%), pneumonia (6.8%
versus 1.4%), and anemia (2.7% versus 0%) [42]. Except for
a sustained improvement in dyspnea, the effects of CYC had
dissipated 12 months after discontinuing treatment [43].
Long-term use of cyclophosphamide is limited due to its
cumulative toxicity.
2.2. Mycophenolate mofetil
In SLS II, in which 142 subjects at 14 US centers received oral
MMF for 24 months or oral CYC for 12 months followed by
placebo for 12 months, there was no significant difference
between groups in the change in FVC % predicted over the
course of 24 months (the primary endpoint). Subjects in both
treatment arms experienced an improvement in FVC % pre-
dicted at month 24 (MMF: 2.2% versus CYC: 2.9%), as well as
improvements in dyspnea [36] and a reduction in the extent of
ILD on HRCT [22]. MMF had better tolerability than CYC, with
fewer premature withdrawals due to adverse events (35%
versus 42%), fewer treatment-related serious adverse events
(4% versus 10%), and lower rates of leukopenia (41% versus
6%) and thrombocytopenia (6% versus 0%). Over twice as
many deaths occurred in the CYC group (11 versus 5) with
most attributed to progression of ILD [36].
2.3. Autologous hematopoietic stem cell transplantation
The latest treatment guidelines issued by EULAR included
a recommendation for use of autologous hematopoietic stem
cell transplantation (HSCT) in patients with rapidly progressive
SSc at risk of organ failure, while emphasizing the need for care-
ful assessment of the risk-benefit profile for the individual patient
[35]. In high-risk patients with progressive dcSSc, HSCT has been
associated with a substantial improvement in long-term survival,
but with significant mortality in the year following transplant. In
the Autologous Stem Cell Transplantation International
Scleroderma (ASTIS) trial in 156 patients with early dcSSc (includ-
ing 125 patients with ILD), HSCT was associated with high treat-
ment-related mortality in the first 12 months (10.1% versus 0%
with CYC) [45]. Causes of treatment-related death were variable
and included Epstein-Barr virus, lymphoma, acute respiratory
distress syndrome, heart failure, and myocardial infarction.
However, at month 12, event-free survival was significantly
greater with HSCT than CYC (HR 0.52 [95% CI 0.28, 0.96]). At
month 24, there were significant improvements from baseline
with HSCT versus CYC in FVC % predicted (6.3% versus −2.8%)
and total lung capacity % predicted (5.1% versus −1.3%) and
non-significant changes in DLco % predicted (−4.7% versus
−4.1%) and residual volume (−4.8% versus −2.1%) [45]. In the
Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial
in 75 subjects with dcSSc and renal or pulmonary involvement
(including 73 subjects with ILD), HSCT was associated with
improved event-free (74% versus 47%) and overall (86% versus
51%) survival at month 72 versus CYC [46]. Of note, treatment-
related mortality in the first year in patients who received HSCT
was lower in the SCOT trial than in the ASTIS trial (0% versus
10%). The reasons for this difference in treatment-related mor-
tality in the first year are unknown, but may be due to differences
in how patients were selected for inclusion, differences in the
pre-transplant conditioning protocols, the higher proportion of
smokers in the ASTIS trial, and/or that the SCOT trial was con-
ducted at more highly specialized SSc centers.
2.4. Lung transplantation
The use of lung transplantation in patients with SSc requires
discussion due to concerns over whether esophageal dysfunc-
tion and gastro-esophageal reflux may cause damage to the
transplanted lung, and whether the multimorbidity of patients
with SSc will impact outcomes. However, recent data suggest
that post-transplant outcomes, including graft dysfunction
and survival, are similar in selected patients with SSc-ILD as
in those with other types of ILD [47–49].
3. Therapies in clinical development
There is a high unmet need for effective and well-tolerated
treatments for SSc-ILD. Modifying the course of disease to
improve outcomes for patients remains the aspiration for the
development of new treatments. A large number of therapies,
with a variety of mechanisms of action, are under investigation
(Figure 2). Here we summarize the clinical trials that have/had
change in lung function as a primary endpoint or demonstrated
potentially meaningful changes in lung function in a Phase 2
study. Ongoing and recently completed Phase 2/3 trials of
potential therapies for SSc-ILD are shown in Tables 1 and 2.
3.1. Nintedanib
Nintedanib, an inhibitor of tyrosine kinases involved in the
pathophysiology of fibrosis, slows lung function decline in
patients with idiopathic pulmonary fibrosis (IPF) [50] and is an
approved treatment for IPF. Nintedanib was investigated as
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a potential treatment for SSc-ILD based on the clinical and
mechanistic similarities between IPF and SSc-ILD [51]. Across
a variety of animal models of SSc, including the bleomycin
model, Tsk-1 model, GvHD model and Fra-2 transgenic mice,
nintedanib has shown consistent antifibrotic effects, in addition
to effects on inflammation and vascular remodeling [51–54].
The efficacy and safety of nintedanib in patients with SSc-
ILD were assessed in the Phase III SENSCIS® trial [55]. Subjects
with onset of first non-Raynaud symptom ≤7 years before
screening, ≥10% extent of fibrosis of the lungs on HRCT, FVC
≥40% predicted and DLco 30–89% predicted were rando-
mized to receive oral nintedanib (n = 288) or placebo
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Figure 2. Nintedanib reduces the rate of decline in forced vital capacity in patients with SSc-ILD: results of the randomized placebo-controlled SENSCIS trial [55].
From Distler et al. Copyright © (2019) Massachusetts Medical Society.
Reprinted with permission.
Table 1. Ongoing and recently (2019) completed randomized controlled Phase II/III trials of investigational therapies for SSc-ILD in which change in lung function is
the primary endpoint.
Drug
(company/funding of study) Type of molecule
Trial name
(ClinicalTrials.
gov identifier) Phase Patient population
Sample
size
(random-
ized)
Primary
endpoint
Estimated
primary
completion
date*
Nintedanib
(Boehringer Ingelheim)
Tyrosine kinase
inhibitor
SENSCIS®
(NCT02597933)
III SSc-ILD 580 Annual rate of
decline in FVC
(mL/year)
over 52 weeks
Completed
Nintedanib
(Boehringer Ingelheim)
Tyrosine kinase
inhibitor
INBUILD®
(NCT02999178)
III Non-IPF fibrosing ILDs with
progressive phenotype
663 Annual rate of
decline in FVC
(mL/year)
over 52 weeks
Completed
Rituximab
(study funded by UK
Medical Research
Council and National
Institute for Health
Research)
CD20-directed
cytolytic antibody
RECITAL
(NCT01862926)
II/III CTD-ILDs 116 Change from
baseline in
FVC (mL) at
week 24
November 2020
Rituximab
(study funded by
University Hospital,
Tours, France)
CD20-directed
cytolytic antibody
EvER-ILD
(NCT02990286)
III CTD-ILD or IPAF or idiopathic ILD
plus NSIP based on HRCT or
histology plus lack of response to
immunosuppressant
122 Change from
baseline in
FVC %
predicted at
month 6
June 2020
Pirfenidone
(Beijing Continent
Pharmaceutical Co, Ltd)
Pyridone analogue N/A
(NCT03856853)
III SSc-ILD 144 Change from
baseline in
FVC %
predicted at
week 52
February 2021
Pirfenidone
(Roche/Genentech)
Pyridone analogue SLS III
(NCT03221257)
II SSc-ILD patients taking mycophen-
olate
150 Change from
baseline in
FVC %
predicted at
month 18
April 2021
*According to ClinicalTrials.gov (accessed 8 August 2019).
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(n = 288) stratified by the presence of anti-topoisomerase
I antibody. Patients receiving low-dose prednisone and/or
stable background therapy with MMF or methotrexate were
allowed to remain on these therapies. Nintedanib significantly
reduced the annual rate of decline in FVC assessed over
52 weeks (the primary endpoint) versus placebo (−52.4 versus
−93.3 mL/year; difference 41.0 mL/year [95% CI 2.9, 79.0]
p = 0.04) (Figure 2) [55]. Nintedanib reduced the rate of
decline in FVC both in patients who were and were not
receiving mycophenolate at baseline, with a numerically
greater treatment effect in patients who were not taking
mycophenolate. The adverse event profile of nintedanib was
similar to that previously observed in patients with IPF, being
characterized mainly by gastrointestinal events, particularly
diarrhea of mild or moderate severity [56].
The efficacy and safety of nintedanib in patients with pro-
gressive fibrosing ILDs have also been assessed in the
INBUILD® trial. This trial enrolled subjects with ILD diagnoses
other than IPF, including SSc-ILD, who had >10% extent of
fibrosis on HRCT and met criteria for progression of ILD in the
prior 24 months [57,58]. As in the SENSCIS® trial, the primary
endpoint was the annual rate of decline in FVC (mL/year)
assessed over 52 weeks. Results will be reported in
September 2019.
3.2. Pirfenidone
Pirfenidone, a pyridone derivative, is an approved treatment
for IPF that has been shown to slow lung function decline in
this patient population [59]. Pirfenidone has shown anti-
fibrotic and anti-inflammatory effects in vitro and in animal
models of lung fibrosis [60–62] but has not been tested spe-
cifically in animal models of SSc. An analysis of lung tissue
from patients with SSc-ILD suggests that pirfenidone may
exert anti-fibrotic effects by interfering with the hedgehog
signaling pathway [63]. In the LOTUSS trial, 16 weeks’ open-
label pirfenidone was generally well tolerated in patients with
SSc-ILD, but no conclusions could be drawn about its efficacy
given the lack of a comparator group [64]. The efficacy and
safety of pirfenidone plus MMF versus MMF alone in subjects
with SSc-ILD are being investigated in SLS III (NCT03221257).
Target enrollment is 150 subjects with a disease duration of
≤7 years from first non-Raynaud’s symptom, dyspnea, ground-
glass opacification on HRCT, and FVC ≤80% predicted. The
primary endpoint is change from baseline in FVC % predicted
at month 18 and the study is due to be completed in 2021.
3.3. Rituximab
Rituximab is a monoclonal cytolytic antibody against CD20
that acts to deplete B cells [65]. Small open-label trials of
rituximab compared to conventional therapy suggest that
rituximab therapy leads to improvements in FVC and DLco in
patients with SSc-ILD [66,67]. In a post-hoc analysis of 9 sub-
jects with SSc-ILD in the European Scleroderma Trial and
Research (EUSTAR) cohort, there were improvements from
baseline in FVC % predicted with rituximab versus matched
controls (0.4% versus −7.7%) after a median follow-up of 6
months [68]. A follow-up study of 254 patients in the EUSTAR
database treated with rituximab, of whom 58% were treated
for lung involvement, did not show effects on FVC or DLco.
After a median follow-up of 2 years, compared to 9575 control
patients matched for propensity score, rituximab-treated
patients were more likely to have an improvement in skin
fibrosis, but did not have significantly different rates of decline
in FVC or DLco [69]. An ongoing multicenter randomized trial
in the UK, RECITAL, is assessing the efficacy and safety of
rituximab given intravenously at baseline and week 2 versus
monthly intravenous CYC in 116 subjects with ILD associated
with SSc, idiopathic inflammatory myositis, or mixed connec-
tive tissue disease [70]. Changes from baseline in FVC (mL) at
week 24 (primary endpoint) and week 48 will be assessed. The
EvER-ILD trial (NCT02990286) is assessing the efficacy and
safety of rituximab, given at baseline and week 2, added to
MMF, versus MMF alone, in 122 subjects with CTD-ILD, inter-
stitial pneumonia with autoimmune features (IPAF), or
Table 2. Ongoing and recently (2019) completed randomized controlled Phase II/III trials of investigational therapies for SSc-ILD in which change in lung function is
a secondary endpoint.
Drug (company/
funding of study) Type of molecule
Trial name
(ClinicalTrials.gov
identifier) Phase Patient population
Sample
size
Primary
endpoint
Secondary lung
endpoint/s
Estimated
primary
completion
date*
SAR156597 (Sanofi) Interleukin-4/interleukin-13
directed antibody
N/A
(NCT02921971)
II dcSSc 97 Change in
mRSS at
week 24
Changes in FVC
and DLco at
week 24
Completed
Bortezomib (Takeda) Proteasome inhibitor N/A
(NCT02370693)
II SSc with pulmonary
fibrosis, taking
mycophe-nolate
30 Safety over
48 weeks
Change in FVC
at week 48
June 2019
Ifetroban
(Cumberland
Pharmaceuticals)
Antagonist of thromboxane A2/
prostaglandin endoperoxide
receptor
N/A
(NCT02682511)
II dcSSc or SSc-PAH 34 Safety over
56 weeks
Changes in FVC
and DLco at
weeks 12, 26
and 52
December 2020
Lenabasum/
anabasum (Corbus
Pharmaceuticals)
Synthetic endo-cannabinoid RESOLVE-1
(NCT03398837)
III dcSSc 365 CRISS at
week 52
Change in FVC
at month 12
March 2020
Belimumab
(GlaxoSmithKline)
Anti-B-lymphocyte stimulator
monoclonal antibody
N/A
(NCT03844061)
II dcSSc 30 CRISS at
week 52
Changes in FVC
and DLco at
week 52
February 2022
*According to ClinicalTrials.gov (accessed 8 August 2019). CRISS, Combined Response Index for Systemic Sclerosis; mRSS, modified Rodnan Skin Score; PAH,
pulmonary arterial hypertension.
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idiopathic ILD, plus NSIP on HRCT or histology, who have not
responded to immunosuppressant therapy; the primary end-
point is the change from baseline in FVC % predicted at 6
months.
3.4. Tocilizumab
Tocilizumab is an anti-IL-6R monoclonal antibody. IL-6 levels have
been associated with declines in FVC and DLco, as well as mortal-
ity, in patients with SSc-ILD [71]. In the randomized Phase II
FaSScinate trial, in which 87 subjects with progressive SSc received
subcutaneous tocilizumab or placebo for 48 weeks, a clinically
meaningful but not statistically significant reduction in change in
mRSS at week 24 (primary endpoint) was observed with tocilizu-
mab (−3.92 versus −1.22) [72]. Although ILD was not an inclusion
criterion, in an exploratory analysis, fewer patients treated with
tocilizumab than placebo had an FVC decline of >10% predicted
at week 24 (3% versus 19%). In a Phase III trial, FocuSSced, in which
210 subjects with SSc received subcutaneous tocilizumab for
48 weeks, there was no significant difference between tocilizumab
and placebo in the primary endpoint of change in mRSS at week
48 (−6.14 versus −4.41, respectively). In exploratory analyses of
change in FVC % predicted at week 48, the mean change from
baseline at week 48was −0.4% predicted in the tocilizumab group
versus −4.6% predicted in the placebo group [73].
4. Supportive care
Although limited evidence is available on the effectiveness of
non-pharmacologic interventions in patients with SSc [74],
patients with SSc-ILD should be offered supportive care indi-
vidualized to the needs of the patient [75–77]. This should
include patient education and may also include oxygen sup-
plementation, pulmonary rehabilitation, and vaccinations. In
addition, management of extra-pulmonary manifestations of
SSc and of comorbidities is an important part of the overall
care of patients with SSc-ILD [78].
5. Future perspectives
The therapies commonly used in the treatment of SSc-ILD
have, at best, modest efficacy and/or are not supported by
robust evidence from clinical trials. MMF is the most widely
used therapy but has not been tested in a placebo-
controlled trial. The duration of treatment with CYC is lim-
ited due to its toxicity. The use of HSCT, while it has shown
efficacy, is restricted to a small subset of patients at high risk
of severe organ damage and mortality and should be per-
formed at specialized centers due to concerns over treat-
ment-related mortality. Targeted therapies that inhibit key
pathways in the pathogenesis of SSc-ILD are needed to
improve patient outcomes. Although a number of drugs
with different molecular targets are under investigation,
a better understanding of pathophysiological targets and
how these might interact with each other is needed. The
potential influence of immunosuppressant therapy on the
activity of drugs targeting other pathogenic pathways also
needs to be investigated. It is likely that different therapeu-
tic regimens, probably based on combination therapy, will
be most effective for sub-groups of patients with SSc. In
addition, more research is needed to discover biomarkers,
including those based on molecular expression patterns,
which can identify the patients most likely to benefit from
specific therapies and bring a precision medicine approach
to the treatment of SSc [79–81].
6. Conclusions
ILD is a common manifestation of SSc associated with high
mortality, but at present, there is a limited evidence base to
inform best practice in its monitoring and management.
Patients with advanced and/or progressive ILD usually receive
immunosuppressants, but there is a lack of robust evidence to
support their efficacy or guide their use. The results of clinical
trials will provide insights into the potential role of new thera-
pies in the management of SSc-ILD.
7. Expert opinion
There is substantial room for improvement in the screening,
diagnosis, and management of SSc-ILD. Delayed diagnosis of
SSc often leads to delayed referral to specialty care, prevent-
ing patients from receiving the monitoring and management
needed to optimize outcomes [82]. A lack of consensus guide-
lines for screening or early diagnosis of ILD in patients with
SSc results in discrepancies in diagnosis and to delayed and
missed diagnosis of SSc-ILD in clinical practice. Although there
is some promising evidence on the use of biomarkers, these
are not yet validated to an extent that would allow them to be
incorporated into clinical practice. More evidence is needed
on clinical, radiological, serological and molecular markers of
SSc-ILD and its progression to inform identification of patients;
decision-making related to initiation, choice and escalation of
treatment; and individualized counseling of patients. There is
a clear need to establish an expert consensus on the drivers
and timing of screening for SSc-ILD, the detection and predic-
tion of disease progression, and the initiation, change and
escalation of treatment.
Patients with SSc who have a limited extent of ILD on
HRCT, or have stable lung function and minimal symptoms,
may not undergo treatment with immunosuppression.
However, patients whose lung function initially appears to
be stable might show progression during follow-up. Further
research is needed to define the optimal frequency of mon-
itoring of such patients and when and how to re-evaluate
treatment initiation. Further analysis of trajectories of FVC
decline in individual patients, and how such trajectories can
be predicted, is needed to improve patient care. The current
practice of treating patients once worsening has occurred
might be sub-optimal, as the opportunity to treat patients
whose disease is progressing might already have been missed
and these patients might be stable during further follow-up.
As a rare and heterogeneous disease, SSc presents chal-
lenges for clinical trial design, particularly regarding the
selection of patients, the generalizability of results, and the
detection of differences between treatment groups within
a relatively short time frame. Recently, the tyrosine kinase
inhibitor nintedanib was shown to reduce the rate of
1014 O. DISTLER ET AL.
progression of ILD in a broad population of patients with
SSc-ILD. Regulatory authorities are now considering applica-
tions for the approval of nintedanib as a treatment for SSc-
ILD. In addition to trials of new therapies, further research is
needed to assess the efficacy and safety of therapies that
are currently used. In the next few years, it is likely that
treatment options will increase as new therapies tested in
clinical trials show efficacy on lung fibrosis. If so, further
research questions will arise. For example, precision medi-
cine approaches to predict response to a specific treatment
will be required. Research will also be needed into whether
different treatment strategies have additive effects, and
whether immediate combination therapy, rather than
sequential use of individual medications, provides better
outcomes with an acceptable toxicity profile.
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